ARTICLE | Company News

Teva sales and marketing update

December 8, 2014 8:00 AM UTC

Teva launched a liquid formulation of Treanda bendamustine injection in the U.S. to treat chronic lymphocytic lymphoma (CLL) and indolent Beta cell non-Hodgkin lymphoma (NHL). The wholesale acquisition cost (WAC) of the alkylating agent is $1,006.20 per 45 mL vial. ...